Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE 01: Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Solid Tumors
2023-509482-20-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of volrustomig in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of volrustomig combinations and Objective response rate (ORR). Planned start Dec 2024; status: authorised.
02
Drugs
volrustomig
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-509482-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509482-20-00.